The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4).
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Jiyeon Kim
No Relationships to Disclose
 
Sehhoon Park
No Relationships to Disclose
 
Peter G. Mortimer
No Relationships to Disclose
 
Heejung (Rosa) Kim
No Relationships to Disclose
 
Simon Smith
No Relationships to Disclose
 
Emma Dean
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca (I); AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca
 
Yu Jung Kim
No Relationships to Disclose
 
Hyun Ae Jung
Consulting or Advisory Role - AIMEDBIO; Guardant Health; Yuhan
Research Funding - Yuhan
 
Jong-Mu Sun
No Relationships to Disclose
 
Woong-Yang Park
No Relationships to Disclose
 
Jin Seok Ahn
Honoraria - Amgen; AstraZeneca; Bayer; BC World Pharmaceutical; Boehringer Ingelheim; Boryung; Kyowa Kirin; Lilly; Menarini; Nokwon Medical; Novartis; Pfizer; Roche; Samyang; Takeda; Yuhan
Consulting or Advisory Role - Daiichi Sankyo Korea; Guardant Health; ImmuneOncia; Pharmbio Korea; Roche; Therapex; Yuhan
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Keunchil Park
Honoraria - BeiGene; INCYTE
Consulting or Advisory Role - ABION; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Geninus; IMBdx; JNJ
Speakers' Bureau - Boehringer Ingelheim